This experiment addresses the AD Knowledge Gap: "How do vascular factors contribute to AD?" (ranked in top 15 AD gaps). Vascular dysfunction interacts with amyloid pathology and may be an independent driver of cognitive decline.
This experiment addresses the AD Knowledge Gap: "How do vascular factors contribute to AD?" (ranked in top 15 AD gaps). Vascular dysfunction interacts with amyloid pathology and may be an independent driver of cognitive decline.
What is the independent contribution of vascular dysfunction to AD pathogenesis? Can targeting vascular pathways provide additive benefits beyond anti-amyloid therapy?
Hypothesis
Vascular dysfunction contributes to AD through:
Blood-brain barrier breakdown — allows peripheral proteins into brain
Small vessel disease — white matter lesions accelerate decline
Study Design
Vascular-AD Cohort Study
Recruit 600 participants with:
| Group | N | Characteristics | |-------|---|-----------------| | AD + CVD | 200 | AD with confirmed cerebrovascular disease | | AD only | 200 | AD without significant vascular disease | | CVD only | 100 | Vascular cognitive impairment, no AD | | Control | 100 | Normal cognition, no vascular disease |
Does vascular burden predict faster cognitive decline independent of amyloid?
Do vascular interventions (BP control, statins) slow decline in AD patients?
Is there synergy between vascular and amyloid pathology?
Phase 3: Intervention Study (Months 24-48)
Trial design: 2x2 factorial
| Arm | Intervention | |-----|--------------| | A | Standard of care | | B | Intensive vascular risk control | | C | Anti-amyloid (lecanemab) | | D | Intensive vascular + anti-amyloid |
Vascular burden predicts cognitive decline independent of amyloid
Deliverable: Vascular risk score for AD prognosis
Hypothesis 2: Vascular-Amyloid Synergy
Combined pathology > sum of individual effects
Deliverable: Combination therapy targeting both pathways
Hypothesis 3: Vascular as Amyloid Cofactor
Vascular changes facilitate amyloid deposition
Deliverable: Prevention strategy targeting vascular health
Critical Readouts
CBF reduction: When does it occur relative to amyloid?
BBB breakdown: Correlation withCSF/plasma albumin ratio
Treatment response: Does vascular care improve anti-amyloid outcomes?
Model Systems
| System | Use | Strength | |--------|-----|----------| | Human cohort | Primary data | Direct relevance | | 5xFAD x cerebral ischemia model | In vivo | Combined pathology | | iPSC brain microvascular organoids | Mechanism | Human BBB model | | Rodent chronic hypoperfusion model | Vascular | Established model |
Feasibility Assessment
| Factor | Assessment | |--------|------------| | Technical Feasibility | High — MRI, biomarkers established | | Recruitment Feasibility | Moderate — stroke clinics, memory clinics | | Cost Estimate | $12-18M over 4 years | | Timeline | 48 months | | Cross-Disease Value | High — applies to vascular dementia, PD |